NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. | Coherus BioSciences Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments. | Gossamer Bio Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. | Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. | |
Founding Date | Founding Date 2000 | Founding Date 2010 | Founding Date 2015 | Founding Date 2016 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Redwood City, US HQ Camarillo, US | Locations San Diego, US HQ Dublin 2, IE | Locations Cambridge, US HQ Cambridge, US | |
Employees | Employees 1,453 | Employees 30615% decrease | Employees 11820% increase | Employees 16135% increase |
Valuation ($) | Valuation ($) 1.8 b | Valuation ($) 85.6 m | Valuation ($) 208 m | Valuation ($) 452 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $509.3m (FY, 2023) | Revenue (est.) $257.2m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $34.2m (FY, 2023) |
Cost of goods | Cost of goods $128.3m (FY, 2023) | Cost of goods $159m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $381.1m (FY, 2023) | Gross profit $98.3m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($207m) (FY, 2023) | Net income ($237.9m) (FY, 2023) | Net income ($179.8m) (FY, 2023) | Net income ($98.4m) (FY, 2023) |
Operating ⚠ | ||||
Phase II Trials Products | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products 1 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Trials Products Approved | Trials Products Approved 3 (FY, 2021) | Trials Products Approved 1 (FY, 2020) | Trials Products Approved N/A | Trials Products Approved N/A |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 174.5m | Total funding raised $ 480m | Total funding raised $ 50m |